PITTSBURGH--(BUSINESS WIRE)--Noveome Biotherapeutics, Inc., a clinical-stage company focused on the biology of paracrine signaling, today announced the initiation of a phase 2 clinical trial of its novel secretome, ST266, to treat patients with moderate to severe periodontitis, a severe inflammatory condition that leads to damage of the soft tissue and destruction of the bone that supports the tooth. The company is the leading innovator in paracrine signaling for the clinical development of novel biotherapeutic products that work safely and effectively in complex biologic processes.
“ST266 provides essential ‘tools’ at critical stages of the healing process to restore homeostasis within the periodontal microenvironment,” said Kenneth J. Mandell, M.D., Ph.D., Chief Medical Officer of Noveome. “The biological attributes of ST266, including the capacity to modulate inflammation, accelerate impaired wound healing, prevent bone loss and support bone regrowth, suggest that ST266 has the potential to become an important new treatment for those suffering with periodontitis.”
The phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled study of ST266 to evaluate the safety, efficacy, and treatment regimen of topical ST266 in patients with moderate to severe periodontitis. The primary efficacy endpoint of this study is the change from baseline in pocket depth evaluated after 3 months of treatment. Subjects will be followed for 9 months for safety and secondary efficacy endpoints. For additional information on this clinical trial, please visit www.clinicaltrials.gov, Identifier NCT02761993.
Read more: http://www.businesswire.com/news/home/20160615005334/en/Noveome-Initiates-Phase-2-Clinical-Trial-ST266